ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Moderna to Present at Upcoming Investor Conferences in December 2021

November 22, 2021 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 22, 2021--

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences:

  • NASDAQ 45 th Investor Conference on Wednesday, December 1 st at 9:30 a.m. ET
  • Piper Sandler 33 rd Annual Virtual Healthcare Conference on Wednesday, December 1 st at 2:00 p.m. ET

A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna’s website for at least 30 days following the presentation.

ADVERTISEMENT

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20211122006214/en/

CONTACT: Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: RESEARCH INFECTIOUS DISEASES GENETICS CLINICAL TRIALS OTHER HEALTH BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH SCIENCE

SOURCE: Moderna, Inc.

Copyright Business Wire 2021.

PUB: 11/22/2021 08:30 AM/DISC: 11/22/2021 08:32 AM

http://www.businesswire.com/news/home/20211122006214/en